Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/31/11
End: 02/29/12
Due: 02/28/13
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 09/30/14
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 07/31/15
End: 03/31/16
Due: 03/31/17
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers | NCT01570205 | Xigen SA | user2@example.com | None | 2011-07-31 | 2012-02-29 | 2013-02-28 | - | - | 2025-07-14 |
| Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation | NCT02235272 | Xigen SA | user2@example.com | None | 2014-09-30 | 2015-12-31 | 2016-12-31 | - | - | 2025-07-14 |
| Efficacy and Safety of XG-104 for the Treatment of Dry Eye | NCT02235259 | Xigen SA | user2@example.com | None | 2014-09-30 | 2015-02-28 | 2016-02-28 | - | - | 2025-07-14 |
| Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain | NCT02508337 | Xigen SA | user2@example.com | None | 2015-07-31 | 2016-03-31 | 2017-03-31 | - | - | 2025-07-14 |